ATLASATLAS fair value
SEK 317.68
Above fair value · 44% premium
Range: SEK 122–SEK 818Fair valuePrice
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Swedish Orphan Biovitrum AB (publ) stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Nasdaq Stockholm · Sweden
SEK 459.00▲ +1.06%
Prices as of Oct 26, 2026 · SEK
Chance of rising in 1 month
51%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Swedish Orphan Biovitrum AB (publ) in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Swedish Orphan Biovitrum AB (publ)
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Swedish Orphan Biovitrum AB (publ)'s fair value at about SEK 317.68 per share (reasonable range: SEK 122.17 to SEK 817.77). At SEK 459.00, the stock trades 44% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Swedish Orphan Biovitrum AB (publ) a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between SEK 437.60 and SEK 483.68; in 9 out of 10, between SEK 400.43 and SEK 528.57. Estimated annual volatility is 29%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- SEK 152B
- Market cap (USD)
- $15.3B
- P/E ratio
- 116.3
- 52-week high
- SEK 487.00
- 52-week low
- SEK 314.40
- Revenue (12 months)
- SEK 30.6B
- Gross margin
- 78.5%
- Operating margin
- 25.3%
- Net margin
- 4.5%
- Beta
- 0.36
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Swedish Orphan Biovitrum AB (publ) sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks SOBI.ST has traded between SEK 314.40 and SEK 487.00. Today it is 5.8% below that high and 46% above its low.
On the business: net margin is 4.5%; it trades at 116.3 times earnings.
Its beta is 0.36: it tends to move less than the market.
About the company
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care.
Want to see everything about Swedish Orphan Biovitrum AB (publ)?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Swedish Orphan Biovitrum AB (publ) (SOBI.ST) fair value?
About SEK 317.68 per share according to ATLAS (reasonable range: SEK 122.17 to SEK 817.77). With the stock at SEK 459.00, it is 44% above it.
What is the chance SOBI.ST goes up next month?
51%: close to a coin flip. In half of the simulated outcomes, SOBI.ST ends the month between SEK 437.60 and SEK 483.68.
How big is Swedish Orphan Biovitrum AB (publ) and what is its P/E ratio?
Swedish Orphan Biovitrum AB (publ)'s market capitalization is SEK 152B. Its price-to-earnings (P/E) ratio is 116.3: you pay SEK 116.3 for each SEK 1.00 of yearly earnings.
How volatile is SOBI.ST?
ATLAS estimates annual volatility at 29%. In a typical month, half of the outcomes end between SEK 437.60 and SEK 483.68.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer